Retrospective study of an extended-depth-of-focus IOL in the presence of macular disease compared to a control group without macular disease

Session Details

Session Title: Extended-Depth-Of-Focus IOLs I

Session Date/Time: Sunday 15/09/2019 | 14:00-16:00

Paper Time: 14:30

Venue: Free Paper Forum: Podium 1

First Author: : J.Odette USA

Co Author(s): :    K. Waltz   B. Wahl   D. Nguyen                       

Abstract Details

Purpose:

To determine the relative effect on distance acuity, near visual acuity, and secondary outcomes when using an extended depth of focus lens in the presence of macular disease.

Setting:

The setting and data were obtained from a 3 surgeon, private practice setting with an attached surgery center in Austin, Texas.

Methods:

Retrospective record review of 686 eyes of 463 subjects with an extended depth of focus IOL implanted from September of 2016 through May of 2018. Eyes were divided into multiple groups including, but not limited to, normal eyes and eyes with macular disease. Macular disease was graded by a masked, fellowship-trained, vitreoretinal surgeon. 616 eyes were normal and 70 had macular disease. Final visual acuities and outcomes were compared between normal eyes and eyes with macular disease. Uncorrected acuities were recorded at distance and near as well as best corrected acuity at distance for all patients at two months post-operatively.

Results:

Mean UCNVA in normal vs macular disease was, respectively, 0.069 vs 0.168 LogMAR (p>0.0001). Mean BCDVA in normal vs macular disease was 0.025 vs 0.,106 LogMAR (p>0.0001). UCNVA of J4 (0.20 LogMAR) in normal vs macular disease was 95% vs 74% (p>0.0001). UCNVA of J1 (0.0 LogMAR) or better in normal vs macular disease was achieved in 42% vs 23% (p>0.0001). BCDVA of 20/32 (0.20 LogMAR) or better in normal vs macular disease was achieved in 99% vs 90% (p>0.0001). BCDVA of 20/20 (0.0 LogMAR) or better in normal vs macular disease, was achieved in 74% vs 46% (p>0.0001).

Conclusions:

Use of an extended depth of focus IOL in the presence of macular disease results in an average loss of only 5 letters of acuity when compared to normal eyes and is therefore a good option for patients desiring spectacle independence in the presence of concurrent macular disease.

Financial Disclosure:

receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, receives consulting fees, retainer, or contract payments from a competing company